Enhanced humoral and Type 1 cellular immune responses with Fluzone adjuvanted with a synthetic TLR4 agonist formulated in an emulsion.
about
Glucopyranosyl lipid A adjuvant significantly enhances HIV specific T and B cell responses elicited by a DNA-MVA-protein vaccine regimenDevelopment and characterization of synthetic glucopyranosyl lipid adjuvant system as a vaccine adjuvantPotentiating effects of MPL on DSPC bearing cationic liposomes promote recombinant GP63 vaccine efficacy: high immunogenicity and protectionA novel respiratory syncytial virus (RSV) F subunit vaccine adjuvanted with GLA-SE elicits robust protective TH1-type humoral and cellular immunity in rodent modelsTLR4 and TLR7/8 Adjuvant Combinations Generate Different Vaccine Antigen-Specific Immune Outcomes in Minipigs when Administered via the ID or IN RoutesFunctional testing of an inhalable nanoparticle based influenza vaccine using a human precision cut lung slice techniqueImmunopotentiation of trivalent influenza vaccine when given with VAX102, a recombinant influenza M2e vaccine fused to the TLR5 ligand flagellinA synthetic adjuvant to enhance and expand immune responses to influenza vaccinesClinical vaccine development for H5N1 influenza.A De-O-acylated Lipooligosaccharide-Based Adjuvant System Promotes Antibody and Th1-Type Immune Responses to H1N1 Pandemic Influenza Vaccine in MiceAntiviral role of Toll-like receptors and cytokines against the new 2009 H1N1 virus infection.The cytokine network of acute HIV infection: a promising target for vaccines and therapy to reduce viral set-point?Immunomodulatory and physical effects of oil composition in vaccine adjuvant emulsions.Adjuvant solution for pandemic influenza vaccine productionAdjuvanted pandemic influenza vaccine: variation of emulsion components affects stability, antigen structure, and vaccine efficacy.In vitro evaluation of TLR4 agonist activity: formulation effects.Glucopyranosyl Lipid Adjuvant (GLA), a Synthetic TLR4 agonist, promotes potent systemic and mucosal responses to intranasal immunization with HIVgp140.Outlining novel cellular adjuvant products for therapeutic vaccines against cancer.Rapeseed oil and ginseng saponins work synergistically to enhance Th1 and Th2 immune responses induced by the foot-and-mouth disease vaccineMolecular and cellular response profiles induced by the TLR4 agonist-based adjuvant Glucopyranosyl Lipid AParadoxical decrease in the capture and lymph node delivery of cancer vaccine antigen induced by a TLR4 agonist as visualized by dual-mode imaging.Applying TLR synergy in immunotherapy: implications in cutaneous leishmaniasis.A defined tuberculosis vaccine candidate boosts BCG and protects against multidrug-resistant Mycobacterium tuberculosis.Therapeutic Vaccine Strategies against Human Papillomavirus.The TLR4 Agonist Vaccine Adjuvant, GLA-SE, Requires Canonical and Atypical Mechanisms of Action for TH1 Induction.Vaccination with the Surface Proteins MUL_2232 and MUL_3720 of Mycobacterium ulcerans Induces Antibodies but Fails to Provide Protection against Buruli Ulcer.A TLR4 agonist synergizes with dendritic cell-directed lentiviral vectors for inducing antigen-specific immune responsesImmunomodulatory and physical effects of phospholipid composition in vaccine adjuvant emulsions.Transmission-blocking activity of antibodies to Plasmodium falciparum GLURP.10C chimeric protein formulated in different adjuvants.Effects on immunogenicity by formulations of emulsion-based adjuvants for malaria vaccines.A new synthetic TLR4 agonist, GLA, allows dendritic cells targeted with antigen to elicit Th1 T-cell immunity in vivoProtection and Long-Lived Immunity Induced by the ID93/GLA-SE Vaccine Candidate against a Clinical Mycobacterium tuberculosis Isolate.Roadmap to developing a recombinant coronavirus S protein receptor-binding domain vaccine for severe acute respiratory syndromeTherapeutic immunization against Mycobacterium tuberculosis is an effective adjunct to antibiotic treatment.MyD88 and TRIF synergistic interaction is required for TH1-cell polarization with a synthetic TLR4 agonist adjuvantImmunisation with ID83 fusion protein induces antigen-specific cell mediated and humoral immune responses in cattle.Optimized subunit vaccine protects against experimental leishmaniasis.Vaccination with the ML0276 antigen reduces local inflammation but not bacterial burden during experimental Mycobacterium leprae infection.Use of defined TLR ligands as adjuvants within human vaccines.Adjuvants containing natural and synthetic Toll-like receptor 4 ligands.
P2860
Q21089693-93359F33-C39F-4CF8-91B2-140B7828FFE7Q21091066-5CE9BB2C-85B3-4E5D-A5DA-AAA967F89B46Q27305883-E6259880-DF55-4900-81BA-90B0AE248D9DQ27312129-2E830875-A9A1-4BF7-89CE-DBA5B3510123Q27322386-BEA0E5F5-7D80-45A2-ABCD-992013AB1C23Q28535298-C23C35D0-CCE4-421B-9ED7-B00EFD90591BQ28743939-362F274B-C915-436F-ACB7-E691465FFDB2Q28748680-26586631-9337-4D85-B394-70634E701DF7Q30222083-99A3DE1A-CE49-4D7F-8168-7E470FB54263Q30395705-8AA45D62-39B3-451D-B6C6-42C25F0E7ACAQ30403033-3CBD9089-9FF2-4C47-9940-787F9E57CEA3Q30406147-F8787B3A-07A8-4F44-82AD-847E65CEADE6Q30406937-135A4B87-42FF-4597-BBFF-04BE652FA6C4Q30422038-9FAF4502-ACC8-4B76-996E-949C47A8C9ECQ30423178-EEA13301-8730-409E-8FE4-64943941C0AAQ30561113-72633924-3281-4ACF-B2A3-E3F0227DE45FQ31076192-22043D51-BB7D-4EF0-99D2-FCEA601C8850Q33997622-BE830C85-408F-43AD-9E35-8D0239C3729AQ34057759-BB51A939-090C-48D0-9754-84A4D6142BE3Q34532064-68B4A11C-5EEB-4740-B94E-CDDD21568A07Q34995056-77F057B8-3417-457E-A986-DFD8D14381A8Q35029988-B1D5F6F8-3390-4697-B5E4-1E796FD74FD3Q35033838-8B043FFF-8970-428A-8265-E5761C229A17Q35826752-5BA48D3D-CCFB-4A60-875E-99CC4F03B0FAQ35885464-90E9F7B0-55B1-4899-9F38-92A5EED36AA3Q35915755-A408D717-C95B-4DBE-A09C-507217D9C93DQ35990046-95811ECE-EA9C-4F86-A363-26E53FD7AE5BQ35999099-5114B99E-33CC-4AEB-9A8B-23BE58F4A4FDQ36267184-AC7302D8-F3CE-43AA-8574-425ACE7BBB02Q36362230-BC55FAB9-5C8E-489D-9D71-F695953A2B56Q36452968-8669BC37-2BF2-4B39-9D0B-BF7674881DCDQ36555077-DC61F58B-06EE-4848-A915-440A4BA74D62Q36650501-362F0E8A-366E-4270-A22F-89307F078212Q36957252-05F9031E-ECEA-4988-A915-EC85B72A8345Q37243896-1C3897DB-9D49-4C35-9DFF-C2C06ACB8847Q37373474-6393624E-C0B7-4372-BC98-95310FB1C192Q37439440-4825BDAD-FD75-4EAC-8B40-F12B94C614A7Q37451046-08E65920-74BB-4CC6-8B92-8DE88F356086Q37825528-E2B0A011-0310-4899-98A0-F7D24D1E2433Q38124063-1CD32116-892B-4619-BB57-15B310ECA312
P2860
Enhanced humoral and Type 1 cellular immune responses with Fluzone adjuvanted with a synthetic TLR4 agonist formulated in an emulsion.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
2009年學術文章
@zh
2009年學術文章
@zh-hant
name
Enhanced humoral and Type 1 ce ...... ist formulated in an emulsion.
@en
Enhanced humoral and Type 1 ce ...... ist formulated in an emulsion.
@nl
type
label
Enhanced humoral and Type 1 ce ...... ist formulated in an emulsion.
@en
Enhanced humoral and Type 1 ce ...... ist formulated in an emulsion.
@nl
prefLabel
Enhanced humoral and Type 1 ce ...... ist formulated in an emulsion.
@en
Enhanced humoral and Type 1 ce ...... ist formulated in an emulsion.
@nl
P2093
P1433
P1476
Enhanced humoral and Type 1 ce ...... ist formulated in an emulsion.
@en
P2093
Farah Mompoint
Malcolm S Duthie
Narek Shaverdian
Rhea N Coler
Susan L Baldwin
Sylvie Bertholet
Tara Evers
Thomas S Vedvick
Vanitha S Raman
Yasuyuki Goto
P304
P356
10.1016/J.VACCINE.2009.07.081
P407
P577
2009-08-11T00:00:00Z